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diabetic foot infection but our model had several limitations/
assumptions; consequently, the results should be interpreted
cautiously. More clinical studies to evaluate oral antibiotics effec-
tiveness are needed.
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OBJECTIVE: Posaconazole has been demonstrated to be signiﬁ-
cantly superior to standard azole therapy in preventing invasive
fungal infections (IFIs) (P < 0.001) and in reducing overall mor-
tality (P = 0.048) among patients with prolonged neutropenia. In
this study, cost-effectiveness of posaconazole was evaluated from
the Canadian health care system perspective. METHODS: A
trial-based decision analytical model was developed. Patients
were assumed to receive prophylaxis with posaconazole or stan-
dard azole therapy (ﬂuconazole, 81%; itraconazole, 19%). The
probabilities of experiencing an IFI, IFI-related death, and all-
cause mortality over 100 days post treatment were estimated. To
extrapolate results beyond the trial period, the model was
extended to a lifetime horizon using 1-month Markov cycles in
which mortality rate is speciﬁc to the underlying disease as esti-
mated from Statistics Canada and Surveillance, Epidemiology,
and End Result (SEER) data. Pharmacotherapy and treatment
costs associated with IFIs were estimated using published litera-
ture. The model was used to estimate costs, IFIs avoided, life-
years gained, and the incremental cost-effectiveness ratio (ICER)
of posaconazole versus standard azole therapy (2007 Canadian
dollars). RESULTS: Posaconazole is associated with signiﬁcant
fewer IFIs (0.05 vs. 0.11) (P = 0.003), increased life-years (0.744
vs. 0.728), and (excluding costs of the underlying condition)
slightly lower costs ($7147 vs. $7332) per patient relative to
standard azole therapy over a lifetime horizon. A second-order
probabilistic Monte Carlo sensitivity analysis was conducted to
assess the effects of parameter uncertainty, particularly as they
relate to treatment efﬁcacy and the costs of an IFI. Results indi-
cate that there is a 53% probability that posaconazole is cost
saving versus standard azole therapy and a 70% probability that
the ICER for posaconazole is at or below the $50,000 per life-
year saved threshold. CONCLUSION: In addition to the proven
efﬁcacy, posaconazole appeared to be cost saving relative to
standard azole therapy in the prevention of IFIs among high-risk
neutropenic patients.
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OBJECTIVE: Hepatitis C is a disease affecting approximately
180 million people worldwide (WHO 2006) and is one of the
main causes of chronic hepatic disease. HCV infection
progresses to chronic form in 80% of infected individuals.
Approximately 20% progress to cirrhosis over 20 years and,
consequently, a high risk of developing hepatocellular carci-
noma population. We assessed the incremental cost-effectiveness
ratio (ICER) of peginterferon alfa-2a (40 KD) plus ribavirin
(PEG + RBV) versus interferon alfa-2b plus ribavirin
(IFN + RBV) in the treatment of patients with chronic hepatitis
C under the Brazilian payer perspective. METHODS: A
Markov model was built to estimate the clinical and economic
impact related to the incorporation of peginterferon-alfa-2a (40
KD). Clinical stages were based on liver histology, forms of
cirrhotic decompensation, liver cancer and liver transplantation.
A Delphi panel was performed for evaluating the direct medical
resources related to each clinical stage in chronic hepatitis C, as
well as costs from treatment with peginterferon-alfa-2a (40
KD), interferon alfa-2b and ribavirin. Effectiveness of treatment
with peginterferon-alfa-2a (40 KD) was obtained from a mul-
ticenter, controlled, randomized trial involving 1121 naive
patients with chronic hepatitis C (Fried et al, 2002). The model
comprises a life-time horizon. We have assumed a discount rate
of 3% for both costs and outcomes according to international
recommendations (Gold et al, 1996). A sensitivity analysis was
conducted using second-order Monte Carlo simulation. Tested
parameters were costs per stage, treatment costs, discount rate,
response rate to treatment, inﬂation rate and early patient dis-
tribution. RESULTS: The ICER of PEG + RBV versus no treat-
ment was approximately -R$62,521 per quality-adjusted life
year (QALY) gained. The ICER of PEG + RBV versus
IFN + RBV was approximately -R$20,087 per QALY. CON-
CLUSION: The study suggests peginterferon alfa-2a (40 KD)
and ribavirin to be a dominant therapy for treating hepatitis C
in the private health care system in Brazil.
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OBJECTIVE: Tipranavir plus ritonavir (TPV/r) and an optimized
background (OB) antiretroviral regimen delays virologic failure,
reduces viral load and increases CD4 count compared to patients
treated with comparator protease inhibitors, co-administered
with ritonavir (CPI/r) and OB alone. The objective was to inves-
tigate the long-term cost, outcomes and cost-effectiveness of
TPV/r + OB compared to CPI/r + OB in the Canadian health care
system. METHODS: A Markov model was developed and popu-
lated with information on 48-week viral load and CD4 cell count
response from two randomized controlled trials (RESIST 1 and
RESIST 2) and HAART-era published literature. Resource use
and cost data was obtained from a Canadian study and published
sources. Future costs and outcomes were discounted at 5%. The
analysis calculated costs and outcomes from time of starting
these regimens, until 90% of patients in each strategy had died
(lifetime analysis). Cost-effectiveness was calculated as cost per
life year (LY) gained and cost per quality-adjusted life year
(QALY) gained. RESULTS: Total discounted lifetime costs
for TPV/r + OB was $221,541 compared to $194,466 with
CPI + OB. discounted life expectancy and QALYs were greater
for TPV/r + OB compared to CPI/r + OB by 0.530 yrs and
0.516 QALYs, respectively. Incremental cost-effectiveness of
TPR/r + OB was $51,058 per LY gained and $52,517 per QALY
gained. Sensitivity analysis showed results were robust. CON-
CLUSION: TPV/r + OB provides superior clinical improvement
to a population of highly treated HIV patients with limited
treatment options. TPV/r + OB is predicted to improve life
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expectancy and QALYs compared to CPI/r + OB with an incre-
mental cost per additional year of life gained of $51,058 and
the incremental cost per QALY of $52,517.
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OBJECTIVE: Invasive fungal infections (IFIs) have emerged as
the major infection-related cause of morbidity and mortality in
patients undergoing transplantations. A recent RCT in allogeneic
hematopoietic stem cell transplantation (HSCT) recipients with
grade 2–4 or extensive chronic graft-versus-host disease com-
pared the efﬁcacy of posaconazole and ﬂuconazole in the preven-
tion of IFIs. At the end of the ﬁxed 112-day treatment period,
posaconazole was as effective as ﬂuconazole in preventing IFIs
(5% vs. 9%); signiﬁcantly reduced breakthrough Aspergillus
infections (2% vs. 7%, p = 0.0059); and decreased IFI-related
mortality (1% vs. 4%; p = 0.0413). We evaluated posaconazole
cost-effectiveness from the Canadian health care system perspec-
tive. METHODS: A trial-based decision-analytic model was
developed. The probabilities of experiencing an IFI, IFI-related
death, and death from other causes over 112 days post treatment
were estimated. To extrapolate results beyond the trial, the model
was extended to a lifetime horizon using 1-month Markov cycles
in which mortality rate was speciﬁc to the underlying disease
obtained from clinical data. Pharmacotherapy and IFI-related
costs were estimated using published literature. The model was
used to estimate costs, life-years saved (LYS), and the incremental
cost-effectiveness ratio (ICER) of posaconazole vs. ﬂuconazole
(2007 CND$). RESULTS: Posaconazole appeared to be more
effective with increased LYS (7.95 vs. 7.81) however, more costly
($16,784 vs. $11,760) than the alternative over a lifetime
horizon. The ICER of posaconazole was $34,668/LYS compared
to ﬂuconazole. A second-order probabilistic Monte Carlo sensi-
tivity analysis was conducted to assess the effects of parameter
uncertainty, particularly concerning treatment efﬁcacy and costs
of IFIs. There was a 4% probability that posaconazole was both
more effective and less costly than Fluconazole, and a 66%
probability that posaconazole ICER was at or below the
$50,000/LYS threshold. CONCLUSION: In addition to the
proven efﬁcacy, posaconazole appeared to be cost-effective rela-
tive to ﬂuconazole in the prophylaxis of IFIs among patients
undergoing allogeneic HSCT.
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OBJECTIVE: To evaluate the cost-effectiveness of vancomycin
versus linezolid in complicated skin and soft tissue infections
(cSSTIs) with methicillin-resistant Staphylococcus aureus
(MRSA) using a decision analytic (DA) model. METHODS: A
decision model was created to evaluate the cost-effectiveness of
vancomycin and linezolid in the treatment of MRSA cSSTIs.
Outcome probabilities were determined from published clinical
trials. The main dependent variables of interest were: total
direct costs, cost-effectiveness ratios (CER), and incremental
cost-effectiveness ratio (ICER). Univariate (one-way) sensitivity
analyses were conducted for all probabilities and costs used in
the model. Second-order Monte Carlo simulation (probabilistic
sensitivity analysis) using 10,000 samples was also performed
to test for robustness, and an acceptability curve was plotted
along a willingness to pay axis. RESULTS: The DA model pre-
dicted that linezolid was the most cost-effective strategy from
the base-case analysis. Average CER for linezolid and vanco-
mycin were 11,089.70 (USD/cure) and 16,299.75 (USD/cure),
respectively. Univariate sensitivity analyses revealed that vanco-
mycin IV duration and linezolid responder probability were
sensitive across the range. Other parameters did not signiﬁ-
cantly change the base-case result. Probabilistic sensitivity
analysis showed that a majority of the points favored linezolid
being dominant over vancomycin. Acceptability curve showed a
95% probability that linezolid was the most cost-effective
strategy with a willingness to pay up to 200,000 (USD)/cure.
CONCLUSION: Based on this decision model, linezolid was
the most cost-effective strategy compared to vancomycin pri-
marily because of shorter IV duration and higher responder
probability.
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OBJECTIVE: Oseltamivir has been shown to reduce the duration
of inﬂuenza symptoms in children, but recent reports of neuro-
psychiatric adverse events deserve consideration. This study
investigated the effect that these adverse events have on the
estimated cost-effectiveness of oseltamivir treatment in children.
METHODS: A decision analytic model was developed to project
the costs and effectiveness of three clinical options for otherwise
healthy ﬁve to eleven year old children with inﬂuenza-like illness:
no antiviral treatment, rapid testing for inﬂuenza and treatment
with oseltamivir if test is positive, and empirical oseltamivir
treatment. The main outcome measure was the incremental cost-
effectiveness ratio (ICER) of each intervention, in dollars per
quality adjusted life year (QALY) gained. Deterministic and
probabilistic sensitivity analyses were performed to quantify
the effects of parameter uncertainty. RESULTS: In the base
case analysis, which assumed neuropsychiatric adverse events
occurred in 0.065% of treated patients, the test and treat
strategy led to an ICER of $30,800 (95% CI: $12,700 to
$207,700) per QALY gained, compared to no antiviral treat-
ment. Empirical treatment was a more costly, but more effective
strategy, with an ICER of $62,500 (95% CI: cost-saving to
$2,138,300) per QALY gained. When the probability of neurop-
sychiatric adverse events was increased to 10 times the baseline
estimate (0.65%), the test and treat strategy led to an ICER of
$32,300/QALY, while empirical treatment was associated with
an ICER of $75,000/QALY. These ratios increased to $53,300
and $410,000, respectively, when this adverse event rate was
raised to 100 times its baseline value (6.5%). CONCLUSION:
Despite recent concern surrounding the risk of neuropsychiatric
adverse events, the use of oseltamivir is projected to remain a
cost-effective treatment option in this pediatric population. This
conclusion is robust to substantial increases in the likelihood of
these events, particularly when oseltamivir is used in conjunction
with rapid testing for inﬂuenza.
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